Jana Bieblova
Overview
Explore the profile of Jana Bieblova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oleksak P, Psotka M, Vancurova M, Sapega O, Bieblova J, Reinis M, et al.
J Enzyme Inhib Med Chem
. 2021 Jan;
36(1):410-424.
PMID: 33440995
Twelve novel analogs of STAT3 inhibitor BP-1-102 were designed and synthesised with the aim to modify hydrophobic fragments of the molecules that are important for interaction with the STAT3 SH2...
2.
Sapega O, Mikyskova R, Bieblova J, Mrazkova B, Hodny Z, Reinis M
Int J Oncol
. 2018 Sep;
53(5):1997-2009.
PMID: 30226595
Cellular senescence is the process of the permanent proliferative arrest of cells in response to various inducers. It is accompanied by typical morphological changes, in addition to the secretion of...
3.
Mikyskova R, Indrova M, Stepanek I, Kanchev I, Bieblova J, Vosahlikova S, et al.
Oncoimmunology
. 2017 Dec;
6(12):e1362528.
PMID: 29209567
Dendritic cell (DC)-based vaccines pulsed with high hydrostatic pressure (HHP)-inactivated tumor cells have recently been shown to be a promising tool for prostate cancer chemoimmunotherapy. In this study, DC-based vaccines,...
4.
Simova J, Sapega O, Imrichova T, Stepanek I, Kyjacova L, Mikyskova R, et al.
Oncotarget
. 2016 Jul;
7(34):54952-54964.
PMID: 27448982
Standard-of-care chemo- or radio-therapy can induce, besides tumor cell death, also tumor cell senescence. While senescence is considered to be a principal barrier against tumorigenesis, senescent cells can survive in...
5.
Fiserova A, Richter J, capkova K, Bieblova J, Mikyskova R, Reinis M, et al.
Int J Oncol
. 2016 Jun;
49(2):763-72.
PMID: 27279019
To elucidate the immunological mechanisms critical for tumor progression, we bred novel mouse strains, different in the NKC and H-2D domains. We used inbreeding to generate hybrids of Balb/c and...
6.
Mikyskova R, Stepanek I, Indrova M, Bieblova J, Simova J, Truxova I, et al.
Int J Oncol
. 2016 Jan;
48(3):953-64.
PMID: 26718011
High hydrostatic pressure (HHP) has been shown to induce immunogenic cell death of cancer cells, facilitating their uptake by dendritic cells (DC) and subsequent presentation of tumor antigens. In the...
7.
Vlkova V, Stepanek I, Hruskova V, Senigl F, Mayerova V, Sramek M, et al.
Oncotarget
. 2014 Jul;
5(16):6923-35.
PMID: 25071011
Downregulation of MHC class I expression on tumour cells, a common mechanism by which tumour cells can escape from specific immune responses, can be associated with coordinated silencing of antigen-presenting...
8.
Mikyskova R, Indrova M, Vlkova V, Bieblova J, Simova J, Parackova Z, et al.
J Leukoc Biol
. 2014 Jan;
95(5):743-753.
PMID: 24389335
MDSCs represent one of the key players mediating immunosuppression. These cells accumulate in the TME, lymphoid organs, and blood during tumor growth. Their mobilization was also reported after CY therapy....
9.
Rosalia R, Stepanek I, Pollakova V, Simova J, Bieblova J, Indrova M, et al.
Immunobiology
. 2012 Nov;
218(6):851-9.
PMID: 23182710
CD4(+)CD25(+)Foxp3(+) T regulatory cells (Tregs) and CD1d-restricted invariant natural killer T (iNKT) cells are two cell types that are known to regulate immune reactions. Depletion or inactivation of Tregs using...
10.
Mikyskova R, Indrova M, Pollakova V, Bieblova J, Simova J, Reinis M
J Immunother
. 2012 May;
35(5):374-84.
PMID: 22576342
Myeloid-derived suppressor cells (MDSC) play an important role in tumor escape from antitumor immunity. MDSC accumulate in the lymphoid organs and blood during tumor growth and their mobilization was also...